Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of interleukin-1 receptor antagonist and medicinal composition thereof

一种药物、用途的技术，应用在白细胞介素-1受体拮抗剂的用途及其药物组合物领域，能够解决限制应用、安全性未被完全证实等问题，达到减少体重降低、改善不良反应、减少腹泻的效果

Active Publication Date: 2010-04-07
USYNOVA PHARM
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the safety of these growth factors has not been fully confirmed. Some scholars believe that growth factors can promote the growth of tumor cells with growth factor receptors, thus limiting the application of such drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of interleukin-1 receptor antagonist and medicinal composition thereof
  • Application of interleukin-1 receptor antagonist and medicinal composition thereof
  • Application of interleukin-1 receptor antagonist and medicinal composition thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0106] (Protective effect of IL-1Ra prophylactic drug on the small intestine of chemotherapy mice) Protective effect of IL-1Ra prophylactic drug on the small intestine in single-dose cyclophosphamide chemotherapy mice.

[0107] Balb / c mice, SPF grade for 8 weeks, weighing 23-28 grams, were randomly divided into two groups. The first group was injected with rhIL-1Ra (1 mg / kg b.w.I.P. every 24 days) for 3 consecutive days from Day-3 to Day-1. every hour), and the second group was injected with an equal volume of normal saline (I.P., every 24 hours). CTX was injected 12 hours after the last injection of protein or saline, once (300mg / kg b.w.I.P.). Observation indicators: HE staining of small intestine sections. The small intestine section at 15 cm below the stomach was taken from each mouse, and 4 sections were counted, 10 villi and 10 crypts were counted on each section, and the length was averaged.

[0108] result:

[0109] Small intestine HE staining statistics showed that ...

Embodiment 2

[0116] (Protective effect of IL-1Ra preventive drug on the small intestine of chemotherapy mice) Protective effect of IL-1Ra preventive drug on the small intestine of mice treated with cyclophosphamide chemotherapy for three consecutive days.

[0117] Balb / c mice, SPF grade for 8 weeks, body weight 23-28 grams, were randomly divided into two groups, the first group was injected with rhIL-1Ra (1 mg / kg b.w.I.P.) for 5 consecutive days from Day-5 to Day-1, every every 24 hours), and the second group was injected with an equal volume of normal saline (I.P., every 24 hours). CTX was injected 24 hours after the last injection of protein or saline, and three consecutive injections were made from Day 0 to Day 2 (200 mg / kg b.w.I.P., once every 24 hours). Observation indicators: body weight, food intake, water intake, diarrhea and death.

[0118] result:

[0119] Body weight: During the observation period from Day 0 and later, the mean body weight of the administration group was highe...

Embodiment 3

[0125] (Protective effect of IL-1Ra preventive medication on the small intestine of chemotherapy mice) Protective effect of IL-1Ra preventive medication on the small intestine of twice cyclophosphamide chemotherapy mice: Balb / c mice, SPF grade 8 weeks, body weight 23 ~30 grams, randomly divided into two groups, continuous intraperitoneal injection of 1 mg / kg RhIL-1Ra from Day-3 to Day-1, once a day for 3 consecutive days, the control group was injected with NS (Day-3 to Day-1); Day0 One-time intraperitoneal injection of 200mg / kg cyclophosphamide. One month later, IL-1Ra and CTX were injected for the second time, the method and dosage were the same as above, and the interval between the two CTX injections was 30 days. Observe the mouse body weight and survival rate after the second injection of CTX

[0126] result:

[0127] Body weight levels of mice after two cyclophosphamide chemotherapy (200mg / kg*2 times). During the experiment, the average body weight of the mice in the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of an interleukin-1 receptor antagonist in the field of biological medicine and a medicinal composition thereof. The invention discloses application of the following (a) or (b) protein in preparing a medicament for preventing or treating intestinal mucosal epithelial cell injury disease: (a) the protein of which an amino acid sequence is shown in SEQ ID NO: 1; and (b) the protein which has at least 70 percent of homology with the amino acid sequence in the (a) and has the effect of preventing or treating the intestinal mucosal epithelial cell injury disease. The proteins can effectively prevent or treat the intestinal mucosal epithelial cell injury disease, can reduce diarrhea and body weight loss, and reduce and improve the injury of chemotherapy on small intestines.

Description

technical field [0001] The invention relates to a use and a pharmaceutical composition in the field of biomedicine, in particular to a use of an interleukin-1 receptor antagonist and a pharmaceutical composition. Background technique [0002] The normal small intestinal mucosa is composed of mucosal epithelium, lamina propria and muscularis mucosae. The mucosal epithelium is composed of a continuous single layer of columnar epithelial cells, which is the outermost layer of the mucosa. The epithelium at the root subsides to the lamina propria, forming tubular intestinal crypts. Primitive epithelial cells divide and proliferate at the crypts, then migrate to the top of the villi, and reach physiological maturity during the migration process. Generally, the epithelial cells have complete functions when they reach the middle of the villi. The renewal of the villi of the small intestine is realized by the continuous proliferation and upward replenishment of the aged epithelial c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61P1/00A61P1/12
CPCA61K38/2006C07K14/54A61K38/1709A61P1/00A61P1/12A61P3/00
Inventor 韩伟向砥吴祯乾
Owner USYNOVA PHARM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com